nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2023-27-2-109-115nefr-2225Research ArticleНАБЛЮДЕНИЯ ИЗ ПРАКТИКИPRACTICAL NOTESПрименение дапаглифлозина у коморбидного пациента: новые возможностиThe use of dapaglifl ozin in a comorbid patient: new perspectiveshttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Паневин Тарас Сергеевич, канд. мед. наук», научный сотрудник отдела воспалительных заболеваний суставов, врач-эндокринолог

115522, Россия, Москва, Каширское шоссе, д. 34А

Taras S. Panevin, MD, PhD

34A Kashirskoye shosse, Moscow, 115522

tarasel@list.ruhttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

Елисеев Максим Сергеевич, канд. мед. наук», заведующий лабораторией микрокристаллических артритов, старший научный сотрудник, врач-ревматолог

115522, Россия, Москва, Каширское шоссе, д. 34А

Maxim S. Eliseev, MD, PhD

34A Kashirskoye shosse, Moscow, 115522

elicmax@yandex.ruhttps://orcid.org/0000-0002-9958-8988БобковаА. О.BobkovaA. O.

Бобкова Анастасия Олеговна, врач-ординатор

115522, Россия, Москва, Каширское шоссе, д. 34А

Resident Anastasia O. Bobkova MD

34A Kashirskoye shosse, Moscow, 115522

nasta07041@gmail.comhttps://orcid.org/0000-0001-7353-4087ДимитреваА. Е.DimitrevaA. E.

Димитрева Анастасия Евгеньевна, врач-ревматолог 2-го ревматологического отделения

115522, Россия, Москва, Каширское шоссе, д. 34А

Anastasia E. Dimitreva MD, rheumatologist

34A Kashirskoye shosse, Moscow, 115522

dimitreva88@mail.ruhttps://orcid.org/0000-0002-9755-5760УрумоваМ. М.UrumovaM. M.

Урумова Маргарита Мухарбековна, канд. мед. наук, заведующая 2-го ревматологическим отделением

115522, Россия, Москва, Каширское шоссе, д. 34А

Margarita M. Urumova MD, PhD

34A Kashirskoye shosse, Moscow, 115522

tarasel@list.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Scientific and Research Institute of RheumatologyRussian Federation202308062023272109115Copyright © Паневин Т.С., Елисеев М.С., Бобкова А.О., Димитрева А.Е., Урумова М.М., 20232023Паневин Т.С., Елисеев М.С., Бобкова А.О., Димитрева А.Е., Урумова М.М.Panevin T.S., Eliseev M.S., Bobkova A.O., Dimitreva A.E., Urumova M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2225

Развитие современного мира проявляется, в том числе, увеличением распространённости ожирения и сердечнососудистых заболеваний. Лечение данных состояний сопряжено с необходимостью назначения многокомпонентной терапии, что осложняет контроль за лекарственными взаимодействиями, приводит к снижению комплаентности и полипрагмазии. Большое количество принимаемых лекарственных средств у конкретного пациента диктует необходимость поиска препаратов, назначение которых способствует контролю сразу нескольких заболеваний, может успешно применяться у пациентов со сниженной функцией почек, при наличии сердечно-сосудистых заболеваний. В представленном описании клинического случая демонстрируется пример использования ингибитора натрий-глюкозного котранспортера 2-го типа – дапаглифлозина у пациента с сахарным диабетом 2-го типа, хронической болезнью почек, хронической сердечной недостаточностью и подагрой.

The development of the modern world is manifested, inter alia, by an increase in the prevalence of obesity and cardiovascular diseases. Treatment of these conditions is associated with the need to prescribe multicomponent therapy, which complicates the control of drug interactions, leads to a decrease in compliance and polypharmacy. A large number of drugs taken in a particular patient dictates the need to search for drugs, the appointment of which contributes to the control of several diseases at once, can be successfully used in patients with reduced renal function, in the presence of cardiovascular diseases. The presented description of a clinical case demonstrates an example of the use of a type 2 sodium glucose cotransporter inhibitor – dapagliflozin in a patient with type 2 diabetes mellitus, chronic kidney disease, chronic heart failure and gout. 

дапаглифлозинсахарный диабет 2-го типахроническая сердечная недостаточностьхроническая болезнь почекмочевая кислотаподаграdapagliflozintype 2 diabetes mellituschronic heart failurechronic kidney diseaseuric acidgoutReferencesИнструкция по медицинскому применению лекарственного препарата Форсига (таблетки, покрытые пленочной оболочкой, 5 мг, 10 мг). Регистрационное удостоверение ЛП- 002596 от 21.08.2014 (переоформлено 01.10.2021)Instructions for medical use of the drug Forsiga (film-coated tablets, 5 mg, 10 mg). Registration certificate LP-002596 dated 08/21/2014 (reissued on 10/01/2021)Паневин ТС, Елисеев МС, Шестакова МВ, Насонов ЕЛ. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой. Терапевтический архив 2020;92(5):110–118Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic Archive 2020;92(5):110–118. (In Russ.)]. doi: 10.26442/00403660.2020.05.000633Chung MC, Hung PH, Hsiao PJ et al. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan. JAMA Netw Open 2021;4(11):e2135353. Published 2021 Nov 1. doi:10.1001/jamanetworkopen.2021.35353Chung MC, Hung PH, Hsiao PJ et al. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan. JAMA Netw Open 2021;4(11):e2135353. Published 2021 Nov 1. doi:10.1001/jamanetworkopen.2021.35353Барскова ВГ, Елисеев МС, Денисов ИС и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология 2012; 50(6):15–18Barskova VG, Eliseev MS, Denisov IS, et al. The frequency of metabolic syndrome and concomitant diseases in patients with gout. Data from a multicenter study. Nauchno-prakticheskaya revmatologiya. 2012;50(6):15–18. (In Russ.)Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168(10):1104–1110. doi:10.1001/archinte.168.10.1104Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168(10):1104–1110. doi:10.1001/archinte.168.10.1104Vázquez-Mellado J, Alvarez Hernández E, Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol 2004;18(2):111–124. doi:10.1016/j.berh.2004.01.001Vázquez-Mellado J, Alvarez Hernández E, Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol 2004;18(2):111–124. doi:10.1016/j.berh.2004.01.001Hernández-Cuevas CB, Roque LH, Huerta-Sil G et al. First acute gout attacks commonly precede features of the metabolic syndrome. J Clin Rheumatol 2009;15(2):65–67. doi:10.1097/RHU.0b013e31819c0dbaHernández-Cuevas CB, Roque LH, Huerta-Sil G et al. First acute gout attacks commonly precede features of the metabolic syndrome. J Clin Rheumatol 2009;15(2):65–67. doi:10.1097/RHU.0b013e31819c0dbaZuo T, Liu X, Jiang L et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc. Disord 2016; 16(1): 207. doi: 10.1186/s12872-016-0379-z71Zuo T, Liu X, Jiang L et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc. Disord 2016; 16(1): 207. doi: 10.1186/s12872-016-0379-z71Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2014;2(11):911–922. doi: 10.1016/s2213-8587(14)70004-xScheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2014;2(11):911–922. doi: 10.1016/s2213-8587(14)70004-xBarnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92–100. doi: 10.3810/pgm.2013.09.2698Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92–100. doi: 10.3810/pgm.2013.09.2698Ferrannini G, Hach T, Crowe S et al. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care 2015;38(9):1730–1735. doi: 10.2337/dc15-0355Ferrannini G, Hach T, Crowe S et al. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care 2015;38(9):1730–1735. doi: 10.2337/dc15-0355Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. Journal of the American Society of Hypertension 2014;8(4):262–275.e9. doi: 10.1016/j.jash.2014.01.007Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. Journal of the American Society of Hypertension 2014;8(4):262–275.e9. doi: 10.1016/j.jash.2014.01.007Sano M, Chen S, Imazeki H et al. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials. Journal of Diabetes Investigation 2018;9(3):638–641. doi: 10.1111/jdi.12726Sano M, Chen S, Imazeki H et al. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials. Journal of Diabetes Investigation 2018;9(3):638–641. doi: 10.1111/jdi.12726Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone 2016;82:93–100. doi: 10.1016/j.bone.2015.04.026Meier C, Schwartz AV, Egger A, Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone 2016;82:93–100. doi: 10.1016/j.bone.2015.04.026Lin KM, Lu CL, Hung KC et al. The Paradoxical Role of Uric Acid in Osteoporosis. Nutrients 2019;11(9):2111. Published 2019 Sep 5. doi:10.3390/nu11092111Lin KM, Lu CL, Hung KC et al. The Paradoxical Role of Uric Acid in Osteoporosis. Nutrients 2019;11(9):2111. Published 2019 Sep 5. doi:10.3390/nu11092111Ljunggren Ö, Bolinder J, Johansson L et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism 2012;14(11):990–999. doi: 10.1111/j.1463-1326.2012.01630.xLjunggren Ö, Bolinder J, Johansson L et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism 2012;14(11):990–999. doi: 10.1111/j.1463-1326.2012.01630.xBolinder J, Ljunggren Ö, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism 2013;16(2):159–169. doi: 10.1111/dom.12189Bolinder J, Ljunggren Ö, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism 2013;16(2):159–169. doi: 10.1111/dom.12189Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine 2013;159(4):262. doi: 10.7326/0003-4819159-4-201308200-00007Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine 2013;159(4):262. doi: 10.7326/0003-4819159-4-201308200-00007Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 2013;13(1). doi: 10.1186/1472-6823-13-58Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocrine Disorders 2013;13(1). doi: 10.1186/1472-6823-13-58Дедов ИИ, Шестакова МВ, Майоров АЮ и др. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под редакцией ИИ Дедова, МВ Шестаковой, АЮ Майорова 9-й выпуск. Сахарный диабет. 2019;22(1S1):1–144. https://doi.org/10.14341/DM221S1Dedov II, Shestakova MV, Mayorov AYu et al. “Algorithms for specialized medical care for patients with diabetes mellitus” Edited by I.I. Dedova, M.V. Shestakova, A.Yu. Mayorova 9th edition. Diabetes. 2019;22(1S1):1–144. https://doi.org/10.14341/DM221S1Терещенко СН, Шестакова МВ, Агеев ФТ и др. Целесообразность назначения дапаглифлозина для профилактики неблагоприятных исходов хронической сердечной недостаточности у пациентов со сниженной фракцией выброса. Резолюция совета экспертов. Российский кардиологический журнал 2020;25(5):3919 TTereshchenko SN, Shestakova MV, Ageev FT et al. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology 2020;25(5):3919. (In Russ.)] doi:10.15829/1560-4071-2020-3919Orso F, Fabbri G, Maggioni AP. Epidemiology of heart failure. Handb Exp Pharmacol 2017;243:15-33. doi:10.1007/164_2016_74Orso F, Fabbri G, Maggioni AP. Epidemiology of heart failure. Handb Exp Pharmacol 2017;243:15-33. doi:10.1007/164_2016_74Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25–30Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25–30Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508–511. doi:10.2337/dci19-0074Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43(3):508–511. doi:10.2337/dci19-0074McMurray JJV, Solomon SD, Inzucchi SE et al. DAPAHF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303McMurray JJV, Solomon SD, Inzucchi SE et al. DAPAHF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303Kosiborod MN, Jhund PS, Docherty KF et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPА-HF trial. Circulation. 2020;141(2):90–99. doi:10.1161/CIRCULATIONAHA.119.044138Kosiborod MN, Jhund PS, Docherty KF et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPА-HF trial. Circulation. 2020;141(2):90–99. doi:10.1161/CIRCULATIONAHA.119.044138Verma S, Mazer CD, Yan AT et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation 2019;140(21):1693–1702. doi:10.1161/CIRCULATIONAHA.119.042375Verma S, Mazer CD, Yan AT et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation 2019;140(21):1693–1702. doi:10.1161/CIRCULATIONAHA.119.042375Chilton R, Tikkanen I, Cannon CP et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17(12):1180–1193. doi:10.1111/dom.12572Chilton R, Tikkanen I, Cannon CP et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015;17(12):1180–1193. doi:10.1111/dom.12572Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial [published correction appears in Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20]. Lancet Diabetes Endocrinol 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial [published correction appears in Lancet Diabetes Endocrinol. 2019 Aug;7(8):e20]. Lancet Diabetes Endocrinol 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9Wheeler DC, Stefánsson BV, Jongs N et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9(1):22–31. doi:10.1016/S2213-8587(20)30369-7Wheeler DC, Stefánsson BV, Jongs N et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021;9(1):22–31. doi:10.1016/S2213-8587(20)30369-7Karalliedde J. Кардио- и нефропротективные эффекты глифлозинов помимо снижения уровня гликемии. Российский кардиологический журнал. 2021;26(3):4323. Karalliedde J. The role of SGLT2 inhibitors beyond glucoselowering to cardio-renal protection. Russian Journal of Cardiology 2021;26(3):4323. (In Russ.) doi:10.15829/1560-4071-2021-4323Karalliedde J. Кардио- и нефропротективные эффекты глифлозинов помимо снижения уровня гликемии. Российский кардиологический журнал. 2021;26(3):4323. Karalliedde J. The role of SGLT2 inhibitors beyond glucoselowering to cardio-renal protection. Russian Journal of Cardiology 2021;26(3):4323. (In Russ.) doi:10.15829/1560-4071-2021-4323Чикина МН, Елисеев МС, Желябина ОВ. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология 2020;14(2):97–103Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya. Modern Rheumatology Journal 2020;14(2):97–103. (In Russ.). doi: 10.14412/1996-70122020-2-97-103McGill JB. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Therapy. 2014;5(1):43–63. doi: 10.1007/s13300-014-0063-1McGill JB. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Therapy. 2014;5(1):43–63. doi: 10.1007/s13300-014-0063-1Doblado M, Moley KH. Facilitative glucose transporter 9, a unique hexose and urate transporter. American Journal of Physiology-Endocrinology and Metabolism 2009;297(4):E831– E835. doi: 10.1152/ajpendo.00296.2009Doblado M, Moley KH. Facilitative glucose transporter 9, a unique hexose and urate transporter. American Journal of Physiology-Endocrinology and Metabolism 2009;297(4):E831– E835. doi: 10.1152/ajpendo.00296.2009Caulfield MJ, Munroe PB, O’Neill D et al. SLC2A9 Is a HighCapacity Urate Transporter in Humans. Hattersley A, editor. PLoS Medicine 2008;5(10):e197. doi: 10.1371/journal.pmed.0050197Caulfield MJ, Munroe PB, O’Neill D et al. SLC2A9 Is a HighCapacity Urate Transporter in Humans. Hattersley A, editor. PLoS Medicine 2008;5(10):e197. doi: 10.1371/journal.pmed.0050197List JF, Woo V, Morales E, et al. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes. Diabetes Care 2008;32(4):650–657. doi: 10.2337/dc08-1863List JF, Woo V, Morales E, et al. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes. Diabetes Care 2008;32(4):650–657. doi: 10.2337/dc08-1863Roden M, Merker L, Christiansen AV et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology 2015;14(1). doi: 10.1186/s12933015-0314-0Roden M, Merker L, Christiansen AV et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular Diabetology 2015;14(1). doi: 10.1186/s12933015-0314-0Davies MJ, Trujillo A, Vijapurkar U et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2015;17(4):426–429. doi: 10.1111/dom.12439Davies MJ, Trujillo A, Vijapurkar U et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2015;17(4):426–429. doi: 10.1111/dom.12439Zhao Y, Xu L, Tian D et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2017;20(2):458–462. doi: 10.1111/dom.13101Zhao Y, Xu L, Tian D et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2017;20(2):458–462. doi: 10.1111/dom.13101Xin Y, Guo Y, Li Y et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi Journal of Biological Sciences. 2019;26(2):421–426. doi: 10.1016/j.sjbs.2018.11.013Xin Y, Guo Y, Li Y et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi Journal of Biological Sciences. 2019;26(2):421–426. doi: 10.1016/j.sjbs.2018.11.013

The authors declare that there are no conflicts of interest present.